- Home
- ABUS vs IMOS Comparison
ABUS vs IMOS Comparison
Compare ABUS & IMOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- IMOS
- Stock Information
- Founded
- ABUS 2005
- IMOS 1997
- Country
- ABUS United States
- IMOS Taiwan
- Employees
- ABUS N/A
- IMOS N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- IMOS Semiconductors
- Sector
- ABUS Health Care
- IMOS Technology
- Exchange
- ABUS Nasdaq
- IMOS Nasdaq
- Market Cap
- ABUS 592.8M
- IMOS 551.9M
- IPO Year
- ABUS N/A
- IMOS N/A
- Fundamental
- Price
- ABUS $3.24
- IMOS $15.82
- Analyst Decision
- ABUS Strong Buy
- IMOS
- Analyst Count
- ABUS 4
- IMOS 0
- Target Price
- ABUS $5.50
- IMOS N/A
- AVG Volume (30 Days)
- ABUS 1.3M
- IMOS 36.9K
- Earning Date
- ABUS 05-05-2025
- IMOS 05-08-2025
- Dividend Yield
- ABUS N/A
- IMOS 6.97%
- EPS Growth
- ABUS N/A
- IMOS N/A
- EPS
- ABUS N/A
- IMOS 0.06
- Revenue
- ABUS $6,171,000.00
- IMOS $692,370,614.00
- Revenue This Year
- ABUS $14.57
- IMOS $7.81
- Revenue Next Year
- ABUS $15.84
- IMOS $4.50
- P/E Ratio
- ABUS N/A
- IMOS $13.04
- Revenue Growth
- ABUS N/A
- IMOS 6.27
- 52 Week Low
- ABUS $2.63
- IMOS $12.78
- 52 Week High
- ABUS $4.72
- IMOS $28.78
- Technical
- Relative Strength Index (RSI)
- ABUS 50.09
- IMOS 45.84
- Support Level
- ABUS $2.71
- IMOS $14.99
- Resistance Level
- ABUS $3.32
- IMOS $15.83
- Average True Range (ATR)
- ABUS 0.21
- IMOS 0.86
- MACD
- ABUS 0.00
- IMOS 0.14
- Stochastic Oscillator
- ABUS 63.86
- IMOS 74.15
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
About IMOS ChipMOS TECHNOLOGIES INC.
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.